Rising Prevalence of Various Kidney-related Diseases
Currently, kidney-related issues are increasing across the world. According to the global report on care delivery for kidney diseases, it has been estimated that, globally, one in every 10 people suffer from some kind of kidney disease. For example, according to the information provided by the National Institute of Diabetes and Digestive and Kidney Diseases, the prevalence of CKD (chronic kidney disease) in the general population is at about 14% and over 661,000 Americans are suffering from kidney failure. Of these, 468,000 people are on dialysis, and roughly 193,000 are living with a functioning kidney transplant. In 2013, more than 47,000 US citizens died of kidney diseases. The global prevalence rate is increasing every year. Therefore, the market for renal biomarkers is expected to grow, as they are helpful for the detection of kidney diseases.
Additionally, other factors, such as high prevalence of diabetes and high blood pressure, which lead to renal diseases, along with rapid technological advances in the field of genetics, are driving the market growth.
Issues related to Regulatory and Reimbursement Systems
The lack of proper reimbursement systems around the world is a major restraining factor for the global renal biomarker market. The process of securing reimbursement and funding for a diagnostic test for renal diseases is extremely challenging anywhere in the world. Stakeholders need to recognize what knowledge the payers/purchasers are looking for. This asks for an extensive research and interpretation of a very large amount of data. Moreover, international reimbursement structures vary from country to country, hence, interested parties have to come up now and then with new and effective strategies. Therefore, the strategies need to be altered as per the target market, making it a cumbersome and tedious task. Moreover, the developers and marketers of biomarkers have to go through a time-consuming and resource-intensive regulatory procedure, in order to bring their biomarkers to the market. They not only have to clear the US FDA hurdles, but also have to gain the confidence of the payers to obtain insurance coverage and payment for their devices. As a result, several companies tend to avoid this and altogether drop the idea of entering the market studied. These lengthy reimbursement procedures are expected to hinder the growth of the renal biomarker market over the forecast period.
The US to Lead the Market in North America
In 2017, the US renal biomarker market held the largest market share in North America, due to the presence of high-quality healthcare system, along with the prevalence rate of kidney diseases being high in this region.
Key Developments in the Market:
- December 2017 - Thermo Fisher Scientific acquired Phenom-World.
Reasons to Purchase this Report
- Current and future renal biomarkers market outlook in the developed and emerging markets
- Various perspectives of the market with the help of Porter’s five forces analysis
- The segment expected to dominate the market
- Regions expected to witness fast growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in Excel)
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Prevalence of Various Kidney-related Diseases
6.1.2 High Prevalence of Diabetes and High Blood Pressure, the Leading Cause of Renal Diseases
6.1.3 Rapid Technological Advances in the Field of Genetics
6.2 Market Restraints
6.2.1 Issues related to Regulatory and Reimbursement Systems
6.4 Key Challenges
7. Market Segmentation
7.1 By Biomarker Type
7.1.1 Functional Biomarker
22.214.171.124 Serum Creatinine
126.96.36.199 Serum Cystatin C
188.8.131.52 Urine Albumin
7.1.2 Up-regulated Protein
184.108.40.206 Neutrophil Gelatinase-Associated Lipocalin
220.127.116.11 Kidney Injury Molecule-1
7.2 By Diagnostic Technique
7.2.1 Enzyme-Linked Immunosorbent Assay (Elisa)
7.2.2 Particle-Enhanced Turbidimetric Immunoassay (Petia)
7.2.3 Colorimetric Assay
7.2.4 Chemiluminescent Enzyme Immunoassay (CLIA)
7.2.5 Liquid Chromatography-Mass Spectrometry (LS-MS)
7.3 By End User
7.3.1 Diagnostic Lab
7.3.2 Outpatient Clinic
7.3.3 Research Center
7.4 By Geography
7.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 Australia & New Zealand
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
7.4.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
7.4.5 South America
126.96.36.199 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Beckman Coulter Inc.
9.2 Thermo Fisher Scientific Inc.
9.3 Abbott Molecular Inc.
9.4 Bioporto A/S
9.5 Astute Medical Inc.
9.6 Randox Laboratories Ltd
9.7 Siemens Healthcare Diagnostics Inc.
9.8 Alere Inc.
9.9 F. Hoffmann-La Roche Ag
9.10 List Not Exhaustive
10. Future of the Market
- BECKMAN COULTER INC.
- THERMO FISHER SCIENTIFIC INC.
- ABBOTT MOLECULAR INC.
- BIOPORTO A/S
- ASTUTE MEDICAL INC.
- RANDOX LABORATORIES LTD
- SIEMENS HEALTHCARE DIAGNOSTICS INC.
- ALERE INC.
- F. HOFFMANN-LA ROCHE AG.